Research Article
BibTex RIS Cite

Polikistik Over Sendrom’nda HbA1c ve Fibrokistik Meme Hastalığı Korelasyonu

Year 2020, Volume: 42 Issue: 3, 383 - 389, 27.10.2020

Nur Dokuzeylül Güngör , Tuğba Gürbüz , Nefise Tanrıdan Okçu

https://doi.org/10.7197/cmj.vi.774089

Abstract

Keywords

Fibrokistik Meme Hastalığı, HbA1c, Polikistik Over Sendromu

References

  • 1. Solomon CG. The epidemiology of polycystic ovary syndrome: prevalence and associated disease risks. Endocrinology and metabolism clinics of North America. 1999 Jun 1;28(2):247-63.
  • 2. Trent ME, Rich M, Austin SB, Gordon CM. Quality of life in adolescent girls with polycystic ovary syndrome. Archives of pediatrics & adolescent medicine. 2002 Jun 1;156(6):556-60.
  • 3. Schroeder AK, Tauchert S, Outman O, Dietrich K, Weiss JM. Insulin resistance in polycystic ovary syndrome.Wien Klin Wochenschr. 2003; 115(23): 812-21.
  • 4. Hjollund NH, Jensen TK, Bonde JP, Henriksen TB, Andersson AM, Skakkebæk NE. Is glycosylated haemoglobin a marker of fertility? A follow-up study of first-pregnancy planners. Human reproduction. 1999 Jun 1;14(6):1478-82.
  • 5. Golland IM, Vaughan Williams CA, Shalet SM, Million LH, Elstein M. Lack of predictive value of HbA1 for impaired glucose tolerance in polycystic ovary syndrome. Gynecological Endocrinology. 1989 Jan 1;3(3):229-35.
  • 6. Amin M. Examining the prevalence of Hemoglobin A1C level disorder in women affected with polycystic ovaries syndrome (PCOS) at Imam Ali Hospital, Karaj. International Journal of Medical Research & Health Sciences. 2018;5(10):7-11.
  • 7. Ader DN, South-Paul J, Adera T, Deuster PA. Cyclical mastalgia: prevalence and associated health and behavioral factors. Journal of Psychosomatic Obstetrics & Gynecology. 2001 Jan 1;22(2):71-6.
  • 8. Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, Vierkant RA, Maloney SD, Pankratz VS, Hillman DW, Suman VJ. Benign breast disease and the risk of breast cancer. New England Journal of Medicine. 2005 Jul 21;353(3):229-37.
  • 9. Vorherr H. Fibrocystic breast disease: pathophysiology, pathomorphology, clinical picture, and management. American journal of obstetrics and gynecology. 1986 Jan 1;154(1):161-79.
  • 10. Baron JA, Weiderpass E, Newcomb PA, Stampfer M, Titus-Ernstoff L, Egan KM, Greenberg ER. Metabolic disorders and breast cancer risk (United States). Cancer Causes & Control. 2001 Dec 1;12(10):875-80.
  • 11. D'Amelio R, Farris M, Grande S, Feraudo E, Iuliano A. Incidenza della malattia fibrocistica della mammella in donne con ovaio policistico. Studio clinico-strumentale [Incidence of fibrocystic disease of the breast in women with polycystic ovary. Clinico-instrumental study]. Minerva Ginecol. 2000; 52(9): 321-25.
  • 12. Gumus II, Koktener A, Dogan D, Turhan NO. Polycystic ovary syndrome and fibrocystic breast disease: is there any association?. Archives of gynecology and obstetrics. 2009 Aug 1;280(2):249.
  • 13. Soran A, Talbott EO, Zborowski JV, Wilson JW. The prevalence of benign breast disease in women with polycystic ovary syndrome: a review of a 12-year follow-up. Int J Clin Pract 2005; 59: 795–7.
  • 14. Sarac ZF, Bilgen I. Association between Insulin Resistance and Breast Parenchyma in Women with Polycystic Ovary Syndrome. Turkish Journal of Endocrinology & Metabolism. 2012 Mar 1;16(1).
  • 15. Krishnamoorthy G, Govindarajulu P, Ramalingam V. Serum hormones in human breast cancer subjects. Neoplasma. 1989;36(2):221.
  • 16. Silfen ME, Denburg MR, Manibo AM, Lobo RA, Jaffe R, Ferin M, Levine LS, Oberfield SE. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents. The Journal of Clinical Endocrinology & Metabolism. 2003 Oct 1;88(10):4682-8.
  • 17. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocrine Reviews. 1997 Dec;18(6):774-800. DOI: 10.1210/edrv.18.6.0318.
  • 18. González F, Rote NS, Minium J, Kirwan JP. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism. 2006 Jan 1; 91(1): 336-40.
  • 19. Pasquali R, Stener‐Victorin E, Yildiz BO, Duleba AJ, Hoeger K, Mason H, Homburg R, Hickey T, Franks S, Tapanainen JS, Balen A. PCOS Forum: research in polycystic ovary syndrome today and tomorrow. Clinical endocrinology. 2011 Apr; 74(4): 424-33.
  • 20. Randeva HS, Tan BK, Weickert MO, Lois K, Nestler JE, Sattar N, Lehnert H. Cardiometabolic aspects of the polycystic ovary syndrome. Endocrine reviews. 2012 Oct 1; 33(5): 812-41.
  • 21. Mauvais-Jarvis P, Sitruk-Ware R, Kuttenn F, Sterkers N. Luteal phase insufficiency: a common pathophysiologic factor in development of benign and malignant breast diseases. Commentaries on research in breast disease. 1979;1:25-59.
  • 22. Pfeifer SM, Kives S. Polycystic ovary syndrome in the adolescent. Obstetrics and gynecology clinics of North America. 2009 Mar 1;36(1):129-52.
  • 23. Renuka P, Shakthiya T, Vinodhini VM. Study of Glycated Hemoglobin Levels in Polycystic Ovary Syndrome. Asian Journal of Pharmaceutical and Clinical Research. 2018;11:191-3.
  • 24. Muti P, Quattrin T, Grant BJ, Krogh V, Micheli A, Schünemann HJ, Ram M, Freudenheim JL, Sieri S, Trevisan M, Berrino F. Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiology and Prevention Biomarkers. 2002 Nov 1;11(11):1361-8.
  • 25. Lin J, Ridker PM, Rifai N, Lee IM, Manson JE, Buring JE, Zhang SM. A prospective study of hemoglobin A1c concentrations and risk of breast cancer in women. Cancer research. 2006 Mar 1; 66(5): 2869-75.

Correlation between HbA1c and fibrocystic breast disease among polycystic ovary syndrome

Year 2020, Volume: 42 Issue: 3, 383 - 389, 27.10.2020

Nur Dokuzeylül Güngör , Tuğba Gürbüz , Nefise Tanrıdan Okçu

https://doi.org/10.7197/cmj.vi.774089

Abstract

Objective: The aim of this study is to investigate whether Hemoglobin A1c (HbA1c) levels in polycystic ovary syndrome (PCOS) can predict the risk of fibrocystic breast disease in women applied to the Gynecology&Obstetrics outpatient clinic.
Method: This retrospective study was conducted from January 2018 to February 2020 on 269 women. The subjects were divided into two groups as PCOS group (Group 1) and control group (Group 2), respectively. 
Results: The mean age of all participants was 33.13 ± 1.93 years. Most of the subjects had normal Body mass index (BMI) (35.3%; 25.7 ± 1.44). 50.6 % had the risk of fibrocystic breast disease. The mean age of menarche was 11.36 ± 0.97, and the mean level of HbA1c was 5.57 ± 0.37. FSH (p< 0.001), LH (p< 0.001), HbA1c (p = 0.001), fasting glucose (p = 0.001) and AMH (p = 0.001) were significantly different between the two groups. Prevalence of fibrocystic breast disease and smoking (p=0.03 and 0.02, respectively) were significantly different at HbA1c levels among the control group. There was a statistically significant difference (p=0.04 and 0.04) between the fibrocystic breast disease and HbA1c levels i.e. 5.7≤ HbA1c ≤6 and HbA1c >6 in the control group.
Conclusions: It was concluded that HbA1c cannot be used for assessment of the fibrocystic breast disease in the PCOS women but can predict the fibrocystic breast disease in healthy women. There may be a need for additional diagnostic tests for the PCOS women to assess the fibrocystic breast disease for early treatment. 

Keywords

Fibrocystic Breast Disease, HbA1c, Polycystic Ovary Syndrome

References

  • 1. Solomon CG. The epidemiology of polycystic ovary syndrome: prevalence and associated disease risks. Endocrinology and metabolism clinics of North America. 1999 Jun 1;28(2):247-63.
  • 2. Trent ME, Rich M, Austin SB, Gordon CM. Quality of life in adolescent girls with polycystic ovary syndrome. Archives of pediatrics & adolescent medicine. 2002 Jun 1;156(6):556-60.
  • 3. Schroeder AK, Tauchert S, Outman O, Dietrich K, Weiss JM. Insulin resistance in polycystic ovary syndrome.Wien Klin Wochenschr. 2003; 115(23): 812-21.
  • 4. Hjollund NH, Jensen TK, Bonde JP, Henriksen TB, Andersson AM, Skakkebæk NE. Is glycosylated haemoglobin a marker of fertility? A follow-up study of first-pregnancy planners. Human reproduction. 1999 Jun 1;14(6):1478-82.
  • 5. Golland IM, Vaughan Williams CA, Shalet SM, Million LH, Elstein M. Lack of predictive value of HbA1 for impaired glucose tolerance in polycystic ovary syndrome. Gynecological Endocrinology. 1989 Jan 1;3(3):229-35.
  • 6. Amin M. Examining the prevalence of Hemoglobin A1C level disorder in women affected with polycystic ovaries syndrome (PCOS) at Imam Ali Hospital, Karaj. International Journal of Medical Research & Health Sciences. 2018;5(10):7-11.
  • 7. Ader DN, South-Paul J, Adera T, Deuster PA. Cyclical mastalgia: prevalence and associated health and behavioral factors. Journal of Psychosomatic Obstetrics & Gynecology. 2001 Jan 1;22(2):71-6.
  • 8. Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, Vierkant RA, Maloney SD, Pankratz VS, Hillman DW, Suman VJ. Benign breast disease and the risk of breast cancer. New England Journal of Medicine. 2005 Jul 21;353(3):229-37.
  • 9. Vorherr H. Fibrocystic breast disease: pathophysiology, pathomorphology, clinical picture, and management. American journal of obstetrics and gynecology. 1986 Jan 1;154(1):161-79.
  • 10. Baron JA, Weiderpass E, Newcomb PA, Stampfer M, Titus-Ernstoff L, Egan KM, Greenberg ER. Metabolic disorders and breast cancer risk (United States). Cancer Causes & Control. 2001 Dec 1;12(10):875-80.
  • 11. D'Amelio R, Farris M, Grande S, Feraudo E, Iuliano A. Incidenza della malattia fibrocistica della mammella in donne con ovaio policistico. Studio clinico-strumentale [Incidence of fibrocystic disease of the breast in women with polycystic ovary. Clinico-instrumental study]. Minerva Ginecol. 2000; 52(9): 321-25.
  • 12. Gumus II, Koktener A, Dogan D, Turhan NO. Polycystic ovary syndrome and fibrocystic breast disease: is there any association?. Archives of gynecology and obstetrics. 2009 Aug 1;280(2):249.
  • 13. Soran A, Talbott EO, Zborowski JV, Wilson JW. The prevalence of benign breast disease in women with polycystic ovary syndrome: a review of a 12-year follow-up. Int J Clin Pract 2005; 59: 795–7.
  • 14. Sarac ZF, Bilgen I. Association between Insulin Resistance and Breast Parenchyma in Women with Polycystic Ovary Syndrome. Turkish Journal of Endocrinology & Metabolism. 2012 Mar 1;16(1).
  • 15. Krishnamoorthy G, Govindarajulu P, Ramalingam V. Serum hormones in human breast cancer subjects. Neoplasma. 1989;36(2):221.
  • 16. Silfen ME, Denburg MR, Manibo AM, Lobo RA, Jaffe R, Ferin M, Levine LS, Oberfield SE. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents. The Journal of Clinical Endocrinology & Metabolism. 2003 Oct 1;88(10):4682-8.
  • 17. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocrine Reviews. 1997 Dec;18(6):774-800. DOI: 10.1210/edrv.18.6.0318.
  • 18. González F, Rote NS, Minium J, Kirwan JP. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism. 2006 Jan 1; 91(1): 336-40.
  • 19. Pasquali R, Stener‐Victorin E, Yildiz BO, Duleba AJ, Hoeger K, Mason H, Homburg R, Hickey T, Franks S, Tapanainen JS, Balen A. PCOS Forum: research in polycystic ovary syndrome today and tomorrow. Clinical endocrinology. 2011 Apr; 74(4): 424-33.
  • 20. Randeva HS, Tan BK, Weickert MO, Lois K, Nestler JE, Sattar N, Lehnert H. Cardiometabolic aspects of the polycystic ovary syndrome. Endocrine reviews. 2012 Oct 1; 33(5): 812-41.
  • 21. Mauvais-Jarvis P, Sitruk-Ware R, Kuttenn F, Sterkers N. Luteal phase insufficiency: a common pathophysiologic factor in development of benign and malignant breast diseases. Commentaries on research in breast disease. 1979;1:25-59.
  • 22. Pfeifer SM, Kives S. Polycystic ovary syndrome in the adolescent. Obstetrics and gynecology clinics of North America. 2009 Mar 1;36(1):129-52.
  • 23. Renuka P, Shakthiya T, Vinodhini VM. Study of Glycated Hemoglobin Levels in Polycystic Ovary Syndrome. Asian Journal of Pharmaceutical and Clinical Research. 2018;11:191-3.
  • 24. Muti P, Quattrin T, Grant BJ, Krogh V, Micheli A, Schünemann HJ, Ram M, Freudenheim JL, Sieri S, Trevisan M, Berrino F. Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiology and Prevention Biomarkers. 2002 Nov 1;11(11):1361-8.
  • 25. Lin J, Ridker PM, Rifai N, Lee IM, Manson JE, Buring JE, Zhang SM. A prospective study of hemoglobin A1c concentrations and risk of breast cancer in women. Cancer research. 2006 Mar 1; 66(5): 2869-75.
There are 25 citations in total.

Details

Primary Language English
Subjects Health Care Administration
Journal Section Surgical Science Research Articles
Authors

Nur Dokuzeylül Güngör 0000-0002-7234-3876

Tuğba Gürbüz 0000-0003-3555-3767

Nefise Tanrıdan Okçu 0000-0003-2307-7628

Publication Date October 27, 2020
Acceptance Date September 21, 2020
Published in Issue Year 2020Volume: 42 Issue: 3

Cite

AMA Dokuzeylül Güngör N, Gürbüz T, Tanrıdan Okçu N. Correlation between HbA1c and fibrocystic breast disease among polycystic ovary syndrome. CMJ. October 2020;42(3):383-389. doi:10.7197/cmj.vi.774089